A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic escherichia coli

Benjamin K. Billips, Ryan E. Yaggie, John P. Cashy, Anthony J. Schaeffer, David J. Klumpp

Research output: Contribution to journalArticle

37 Scopus citations

Abstract

Uropathogenic Escherichia coli are the leading cause of urinary tract infection. We recently demonstrated that deletion of the O antigen ligase gene, waaL, from the uropathogenic E. coliisolate NU14 results in a strain that stimulates enhanced urothelial cytokine secretion. Because enhanced innate immune responses are of interest in vaccine development, we examined the therapeutic potential of NU14 ΔwaaL as a vaccine for urinary tract infection. NU14 ΔwaaL stimulated enhanced interleukin-6 secretion by mouse macrophages, compared with secretion by the wild type. Mice vaccinated via instillation into the bladder developed protective responses that prevented persistent colonization after bladder challenge with NU14, yet NU14 ΔwaaL failed to persistently colonize the mouse bladder. Inoculation with the vaccine strain protected mice against challenge with a broad range of clinical uropathogenic E. coli isolates and produced immunity that lasted ≥8 weeks. Therefore, NU14 ΔwaaL is a candidate live-attenuated vaccine for the treatment and prevention of acute and recurrent urinary tract infection by caused by uropathogenic E. coli.

Original languageEnglish (US)
Pages (from-to)263-272
Number of pages10
JournalJournal of Infectious Diseases
Volume200
Issue number2
DOIs
StatePublished - Jul 15 2009

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'A live-attenuated vaccine for the treatment of urinary tract infection by uropathogenic escherichia coli'. Together they form a unique fingerprint.

  • Cite this